英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

syrupy    
a. 糖浆的;似糖浆的

糖浆的;似糖浆的

syrupy
adj 1: overly sweet [synonym: {cloying}, {saccharine}, {syrupy},
{treacly}]
2: having a relatively high resistance to flow [synonym: {syrupy},
{viscous}]
3: with honey added [synonym: {honeyed}, {honied}, {syrupy}]

Sirupy \Sir"up*y\, Syrupy \Syr"up*y\, a.
Like sirup, or partaking of its qualities. --Mortimer.
[1913 Webster]


Syrup \Syr"up\, n., Syrupy \Syr"up*y\, a. [See {Sirup}.]
Same as {Sirup}, {Sirupy}.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
syrupy查看　syrupy　在百度字典中的解释百度英翻中〔查看〕
syrupy查看　syrupy　在Google字典中的解释Google英翻中〔查看〕
syrupy查看　syrupy　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advancing hypoparathyroidism treatment: FDA approval of . . .
    This approval marks a critical milestone in endocrine therapeutics and offers renewed hope for patients struggling with the burdens of chronic HypoPT Keywords: calcium homeostasis, FDA approval, hypoparathyroidism, orphan drug, Palopegteriparatide, parathyroid hormone, Yorvipath
  • Revised European Society of Endocrinology Clinical Practice . . .
    Abstract In the present European Society of Endocrinology (ESE) clinical guideline, we present recommendations for the diagnosis, management, and monitoring of chronic hypoparathyroidism (HypoPT) in adults Management of HypoPT has changed since the first ESE clinical guideline was published in 2015, as has the knowledge on patient burden of the disease, and the understanding of associated
  • YORVIPATH: First Hypoparathyroidism Treatment in Adults
    YORVIPATH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range across the 24-hour dosing period YORVIPATH was granted marketing authorization by the European Commission (EC) in November 2023 as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
  • Palopegteriparatide (YORVIPATH) in Hypoparathyroidism
    Palopegteriparatide (YORVIPATH) in Hypoparathyroidism National Drug Mini-monograph June 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The purpose of VA National Formulary Committee drug monographs is to provide a focused drug review for making formulary decisions
  • FDA approves new drug for hypoparathyroidism, a rare disorder
    The FDA has approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism Yorvipath was not studied in adults with acute post-surgical hypoparathyroidism
  • Chronic Hypoparathyroidism—Current and Emerging Therapies
    Conventional treatment for hypoparathyroidism with calcium salts and activated vitamin D has limitations such as inadequate control of symptomatic hypocalcemia and large pill burden PTH replacement therapy offers a more physiologic alternative to conventional therapy
  • Take Charge of Hypopara | YORVIPATH® (palopegteriparatide)
    Official Patient site for YORVIPATH for chronic hypoparathyroidism in adults See full Prescribing Information Important Safety Information
  • FDA approves hypoparathyroidism treatment Yorvipath
    Hypoparathyroidism is considered chronic if it persists for longer than six months Yorvipath contains palopegteriparatide, a prodrug that is modified in the body over time into teriparatide, a shortened version of PTH that works in a way similar to the naturally occurring, full-length hormone
  • Early U. S. Real-World Treatment Patterns and Outcomes in . . .
    To examine the impact of palopegteriparatide (YORVIPATH; TransCon PTH) on real-world clinical outcomes in adult patients with hypoparathyroidism





中文字典-英文字典  2005-2009